Profile

Identity, professional record and current appointments.

Overview

Professional record at a glance

A concise summary of information supported by the cited public sources. Missing information is treated as unknown, not as a negative finding.

Current roles
22 current organizations shown on this profile
Board positions
22 supported by public sources, 0 supplied by the profile owner
Committee roles
1Roles supported by the sources cited on this profile
Qualifications
Not establishedNo qualification is currently confirmed by the cited sources

Professional narrative

About

Mr. Pucci served as Chief Executive Officer of ArQule (2008-2020), a biopharmaceutical oncology company, guiding it through its acquisition by Merck & Co. He previously held executive roles at Bayer A.G. (2001-2008) and brings extensive global healthcare and biopharmaceutical experience in strategic planning, capital allocation and operational oversight. He serves on the Audit Committee and was previously Lead Independent Director.

Sources are shown with the information they support.

Current roles

Appointments & responsibilities

Board appointments

Governance

Board appointments, committee responsibilities and disclosed relationships.

Board and advisory record

Board service

Sources are shown with each role, education record, or credential.

Director

Replimune Group, Inc.

2020-01-01 · current

Confirmed by public sourceView source

Director

West Pharmaceutical Services

Current · start date not disclosed

Confirmed by public sourceView source

Connections

Explore the roles, education and affiliations published in this record.

Replimune Group, Inc.

Open Replimune Group, Inc. profile →

Director at Replimune Group, Inc.

2020-01-01 → End not stated

current · source reported

Observed: 2026-09-22

Replimune Group, I…Replimune Group, Inc.West Pharmaceutica…West Pharmaceutical ServicesPaolo Pucci

Dashed lines mark past roles. Select a connection to see its dates and sources.

Relationship map

Connected through the public record

Direct relationships from verified facts and published résumé records. Private connections are excluded.

Direct public links only

Only published affiliations are shown here. Private relationships require authorized access.

Experience

Career history, education, credentials and public contributions.

Published record

Featured coverage

Selected publications and public sources used to establish this profile. Inclusion records provenance; it is not an endorsement.

Source 1 · Sec ProxyPublic profile sourceSupports Director at Replimune Group, Inc. (NASDAQ: REPL).Open sourceSource 2 · Sec FilingWST DEF 14A director slateSupports AI and ML experience, Board role, Committee assignments, Cybersecurity experience, Technology background.Open source

Basis

Identifiers, sources, dates and record limitations.

Identifiers

Alpha ID
alpha:person:paolo-pucci
Record version
public-0

Sources

Sources and published information

Each item links to the public source used to support it. When sources disagree, the item is clearly marked for review.

AI and ML experience · Source reportedAI and ML experience: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Board independence · Source reportedIndependent director1 source
Verification
Source reported
Confidence
95%
Last reviewed
May 3, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Board membership · Source reportedServes on the board of Replimune Group, Inc.1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board membership · CorroboratedServes on the board of West Pharmaceutical Services, Inc.Supported by 2 public records2 sources
Verification
Corroborated
Confidence
95%
Last reviewed
May 3, 2026
Board role · Source reportedBoard role: Director1 source
Verification
Source reported
Confidence
92%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Committee assignments · Source reportedNo committee assignment disclosed in the cited filing1 source
Verification
Source reported
Confidence
95%
Last reviewed
May 3, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Committee assignments · Source reportedCommittee assignments: Audit1 source
Verification
Source reported
Confidence
88%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Cybersecurity experience · Source reportedCybersecurity experience: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Technology background · Source reportedTechnology background: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

View all sources6 records
  1. https://www.sec.gov/Archives/edgar/data/1737953/000110465926087650/tm263608-4_def14a.htm

    Sec Proxy · Tier not stated · Reviewed Jul 30, 2026

    Supports: Director at Replimune Group, Inc. (NASDAQ: REPL)

  2. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

    Supports: AI and ML experience · Board role · Committee assignments · Cybersecurity experience · Technology background

  3. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

    Supports: Board membership · Committee assignments · Board independence

  4. https://www.sec.gov/Archives/edgar/data/105770/000110465926026778/wst-20260504xdef14a.htm

    Sec Filing · Tier not stated · Reviewed May 3, 2026

    Supports: Director at West Pharmaceutical Services (NYSE: WST)

  5. https://www.sec.gov/Archives/edgar/data/1737953/000110465926087650/tm263608-4_def14a.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership

  6. https://www.sec.gov/Archives/edgar/data/105770/000110465926026778/wst-20260504xdef14a.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership